Distinct haplotypes and free movement of Aedes aegypti in Port Sudan,Sudan

Any attempt to control a mosquito-borne disease should primarily focus on controlling its vector. In Sudan, arboviral infections are a major health problem where periodical outbreaks of arboviruses transmitted by Aedes aegypti have been reported. This preliminary study was performed to uncover the population genetic diversity of Aedes aegypti from Red Sea State, Sudan, using mtDNA-COI gene. We performed morphological identification, PCR and DNA nucleotide sequencing and analysed the genetic polymorphism, and isolation by distance of Aedes aegypti from four sites. Of the 55 samples successfully sequenced, six haplotypes were revealed. Global haplotype network revealed that the predominant haplotype in Sudan (Hap1; 31 sequences = 56.4%), the second most frequent haplotype (Hap2; 13 sequences = 23.6%) and Hap 5 (3.6%) were identical or genetically close to isolates seen in different countries distributed in the United States, South America, Europe, Asia and two African isolates, one from Kenya and the other from Europa Island (Mozambique Channel). Haplotype 4 (3.6%) appeared closely related to mosquitoes sampled from Cameroon, Kenya, Sri Lanka and India and belonged to a lineage that contained isolates from all over the geographical expansion. Haplotype 6 (1.8%) seemed quite distant from any other sequenced mtDNA. To summarize, four haplotypes were found only in Sudan, and one rare haplotype appeared genetically distant from all other haplotypes, suggesting a local origin. Subdivision measures and testing suggested a probable free (or almost free) migration between the different sites sampled.     

Targeting ERK/COX-2 signaling pathway in permethrin-induced testicular toxicity: a possible modulating effect of matrine

Molecular Biology Reports - Permethrin (PER), the prevalent synthetic pyrethroid, was reported to have genotoxic effects along with male reproductive organs impairment. Matrine, the Chinese herb...     

Formulation development of self-nanoemulsifying drug delivery system of celecoxib for the management of oral cavity inflammation

The oral administration of celecoxib (CLX) is a real problem because of its low aqueous solubility that results in high variability in absorption and its severe adverse effect such as cardiotoxic effects and gastrointestinal toxicity. Self-nanoemulsifying drug delivery systems (SNEDDS) can enhance the poor dissolution and erratic absorption of poorly water-soluble drugs such as CLX. This study was conducted to investigate the potential of SNEDDS to enhance the efficacy of CLX on inflamed mucous tissue and reduce systemic adverse effects by increasing its poor dissolution properties. A pseudo-ternary phase diagram was derived from the results of CLX solubility experiments in various excipients. These studies revealed the use of Labrafil M 2515 CS as oil, tween 80 as a surfactant, and polyethylene glycol 400 as a co-surfactant for the optimization of SNEDDS formulations. Eight formulations were formulated and characterized by their particle size, polydispersity index, viscosity, globular shape, drug solubility, self-emulsification efficiency, in vitro drug release, and permeation. The anti-inflammatory effect of CLX-SNEDDS was evaluated by carrageenan-induced cheek oedema in rats. The cheeks were treated with CLX-SNEDDS before oedema induction and then noticed for narrow periods (2?h) followed by histopathological studies to determine the efficacy of treatment. The selected formulations (F3 and F5) showed spherical morphologies under transmission electron microscopy, mean droplet sizes of 116.9?±?1.78 and 124?±?1.87?nm, respectively, complete in vitro drug release, and high cumulative amounts of drug permeation in 8?h. They also showed significant remarkable cheek oedema inhibition in comparison with the control groups (p?<?0.05). CLX-SNEDDS was found to achieve effective local therapeutic concentration and intended to reduce cheek oedema, congestive capillary, inflammatory cells, and side effects due to lower dose size.     

Edge activators and a polycationic polymer enhance the formulation of porous voriconazole nanoagglomerate for the use as a dry powder inhaler

Purpose: Voriconazole has both low aqueous solubility and stability. We hypothesize that designing voriconazole in the form of a nano powder inhaler at a geometric diameter within 1–5?μm will enhance its stability and solubility. Therefore, we prepared nanoagglomerates of voriconazole which will collapse in the lungs to reform the nanoparticles.

Method: The nanoparticles were formulated using both stearic acid and sodium deoxycholate as edge activators. Osmogenic polycation polyethyleneimine (PEI) was used to form agglomerates of controllable size.

Results: Voriconazole nanoparticles and agglomerates showed a significant higher cumulative drug release than the pure powder (p?R^2?=^?0.95. Small-sized particles were formed (353?nm), while their zeta potential was ?30.7?mV. The agglomerates were 2.7?μm in size and their zeta potential was ?20.9?mV. The formation of porous agglomerates was confirmed using a transmission electron microscope. Cascade impactor was used to evaluate the aerodynamic properties of the nanoparticles and the agglomerates. The aerodynamic characterization of the nanoparticles and the agglomerates resulted in a significant smaller mass median aerodynamic diameter (MMAD) (p?p?p?p?Conclusion: The results suggest that using the combination of edge activators and diluted polycationic polymer solution provides porous voriconazole nanoagglomerates in a respirable range, which is proved successful in enhancing both the deposition and the dissolution of water insoluble-drugs in the lung.